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Abstract
Background: Beta-blockers (BB) are the cornerstone of therapy for heart failure (HF); however, the 
effects of these drugs on the prognosis of patients with concomitant atrial fibrillation (AF) remain 
controversial. The objective of this meta-analysis was to evaluate the efficacy of BB on mortality in HF 
coexisting with AF.
Methods: A systematic search of PubMed, Embase and the Cochrane Library databases was 
conducted. Observational cohort studies and randomized controlled trials reporting outcomes of 
mortality or HF hospitalizations for patients with HF and AF, being assigned to BB treatment.  
A non-BB group was also included.
Results: A total of 8 clinical studies (5 randomized controlled trials and 3 observational cohort stud-
ies) involving 34197 patients were included in the analysis. The pooled analysis demonstrated that BB 
treatment was associated with a 22% reduction in relative risk of all-cause mortality in patients with 
HF and AF (RR: 0.78; 95% CI 0.71–0.86; p < 0.00001; I2 = 27%). The pooled analysis of 5 studies 
reported the outcome of HF hospitalization (2774 patients) which showed that BB therapy was not as-
sociated with a reduction of HF hospitalizations (RR: 0.94; 95% CI 0.79–1.11; p = 0.46; I2 = 38%). 
Conclusions: Meta-analysis suggests the potential mortality benefit of BB in patients with HF and AF.  
It was concluded herein that it is premature to deny patients with AF and HF to receive BB therapy 
considering current evidence. (Cardiol J 2019; 26, 6: 744–752)
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Introduction
Heart failure (HF) and atrial fibrillation (AF) 
are two burdensome cardiovascular epidemics of 
the 21st century [1–3]. Patients with concomitant 
AF and HF have even higher mortality and hos-
pital admission rates [1–5]. Thus, the importance 
of concomitant AF and HF cannot be overstated.
Among the many therapies available for HF 
and AF, beta-blockers (BB) are a cornerstone of 
management [5–8]. Based on several large ran-
domized clinical trials, BB are strongly recom-
mended (IA) for heart failure with reduced ejection 
fraction (HFrEF) by both American and European 
guidelines [5–8]. However, no randomized trials 
have been performed specifically to investigate the 
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efficacy of BB in HF patients with AF. Post-hoc 
analyses of randomized trials designed to assess 
BB in HF suggest no benefit of BB in HF patients 
with AF [9–13]. Furthermore, two recent meta-
analyses have failed to show clearly the mortality 
and morbidity benefit of BB in patients with HF 
and concomitant AF [14, 15]. Of note, the AF 
group comprised only 17–21% of the whole patient 
cohort, and the obtained meta-analyzed results 
might reflect an under-powered analysis; in ad-
dition, the randomized controlled trials (RCTs) 
included in the previous meta-analyses were 
published more than 10 years ago, which was 
different from the current real world. Recently, 
several large well-designed observational cohort 
studies examining the prognostic effect of BB in 
HF and AF has been published after these meta-
analyses were performed [16–18]. 
Given the limited evidence and uncertain ef-
fects of BB in HF with coexisting AF, the aim was 
to conduct an updated meta-analysis of RCTs and 
observational cohort studies (OCSs) on the effect 
of BB on outcome in HF and AF.
Methods
Search strategy
Electronic searches were conducted in the 
PubMed, Embase and the Cochrane Library da-
tabases. Search terms included “beta-blocker”, 
“heart failure”, “atrial fibrillation”, and their vari-
ations. There was no language restriction placed 
on the searches. Each database was searched from 
inception to June 2017. Additionally, reference lists 
in the articles chosen for inclusion, and the refer-
ence lists of previous reviews were screened to 
identify other potentially eligible trials.
Inclusion criteria
Trials with the following characteristics were 
included:
 — Population: Adult patients diagnosed as AF and 
HF (including both heart failure with reduced 
ejection fraction [HFrEF] and heart failure 
with preserved ejection fraction [HFpEF]).
 — Intervention: The intervention group included 
patients who received BB treatment.
 — Control: The control group included patients 
who did not receive BB treatment.
 — Outcomes: The all-cause mortality or HF hospi-
talizations had to be the outcome reported, and 
the duration of follow-up was at least 6 months.
 — Types of study: The studies had to be RCTs 
or OCSs.
Study selection and data extraction
Two authors independently screened titles 
and abstracts. They obtained full articles that met 
the inclusion and exclusion criteria and after an 
independent review.
Information about the study and patient char-
acteristics, methodological quality, intervention 
strategies, and clinical outcomes was systemati-
cally extracted separately by two reviewers. Disa-
greements were resolved by consensus.
Quality assessment
The quality of random control trial included 
was assessed by the Jadad quality scale [19]. The 
quality of the observational study was evaluated 
by the Newcastle-Ottawa Scale tool (available at: 
http://www.ohri.ca/programs/clinical_epidemiol-
ogy/oxford.asp).
Statistical analysis
The relative risks (RRs) and 95% confidence 
intervals (95% CI) were used as the common meas-
ure across the studies. The hazard ratios (HRs) were 
considered equivalent to RRs [20, 21]. If the effect 
estimates were not available in the studies included, 
RRs were calculated by using the following formula: 
RR = Probability of events given treatment/Prob-
ability of events given no-treatment. If the studies 
provided the adjusted estimations, they were directly 
used in the meta-analysis. Statistical heterogeneity 
across studies was assessed by using the Q statistic 
with its p value and I2 statistic. The I2 statistic is 
used to quantify the proportion of total variation in 
the effect estimation that is due to between study 
variations. An I2 value greater than 50% indicates 
significant heterogeneity [22]. Clinical heterogeneity 
could not be excluded, so the pooled RR was calcu-
lated with the random-effects model [23].
Results
Search and selection of studies
The initial search yielded 680 unique titles and 
abstracts from PubMed, Embase and the Cochrane 
Library, and approximately potentially relevant 
articles identified. Of these articles, 5 RCTs [9–13] 
and 3 OCSs [16–18] fulfilled the eligibility criteria 
and were included in the present meta-analysis. 
The details of study selection flow diagram were 
described in Figure 1.
Characteristics and quality of study included
The characteristics of the studies included 
are presented in Table 1. In all 8 studies included, 
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5 studies were randomized controlled design and 
3 studies were observational cohort design. All 
the 5 RCTs were specific AF sub-studies of the 
large HF randomized trials that compared the 
effect of BB with those of placebo. Among the 
3 OCSs, propensity score (PS) analysis was 
performed with PS matching in 2 studies (AF- 
-CHF study and Danish nationwide registry), and 
multivariable-adjusted Cox regression analysis 
was performed in 1 study (Swedish HF Registry). 
Of the 8 studies, patients with HFrEF were in-
cluded in the 6 studies (US-Carvedilol, CIBIS-II, 
MERIT-HF, BEST, Swedish HF Registry and 
AF-CHF); patients with both HFrEF and HFpEF 
were included in 2 studies (SENIORS and Danish 
nationwide registry). A total of 34197 patients 
were enrolled, including 20235 patients treated 
with BB and 13962 without BB. The mean follow-
up duration ranged from 6 months to 3.1 years. For 
the 5 RCTs, study quality was scored as “good” 
for all but one (the US-Carveilol study), which 
was scored as “fair” by using the Jadad quality 
scale. For the 3 OCSs, study quality was scored 
as good (7–9 scores) by using Newcastle-Ottawa 
Scale tool.
Patient characteristics
Patient characteristics of the studies included 
are presented in Table 2. Included patients were 
a mean age of 70 years, 76% were men, mean left 
ventricular ejection fraction was 27.5%, 35% had 
New York Heart Association (NYHA) functional 
class for I/II and 65% had NYHA III/IV. Coronary 
artery disease was common and ranged from 21% 
to 56%, respectively; hypertension and diabetes 
were also common and ranged from 8% to 56% 
and from 13% to 27%, respectively. Baseline medi-
cation included angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker in 84.8% 
of the patients, digoxin in 70%, diuretics in 90% 
and oral anticoagulant in 60%. Baseline heart rate 
of patients was similar among included studies, 
ranging from 79 bpm to 88 bpm. 5 RCTs reported 
the heart rate change at the end of follow-up with 
a mean heart rate reduction of 10.9 bpm.
Effect of beta-blockers on all-cause mortality
All 8 studies reported the outcome of all-cause 
mortality. The effect estimations of HRs were pro-
vided in 5 studies and RRs in 3 studies. The effect 
of BB on all-cause mortality in HF and AF was 
shown in Figure 2. In the pooled analysis of 5 RCTs, 
BB use was associated with non-significant reduced 
risk for mortality (RR 0.97; 95% CI 0.79–1.19, 
p = 0.79; heterogeneity, p = 0.55, I2 = 0). In the 
pooled analysis of 3 OCSs, BB use was associated 
with improved survival (RR 0.74; 95% CI 0.71–0.78, 
p < 0.00001; heterogeneity, p = 0.22, I2 = 0). Over-
all, use of BB reduced risk for mortality by 22% (RR 
0.78; 95% CI 0.71–0.86, p < 0.00001; heterogeneity, 
p = 0.26, I2 = 27%). 
Effect of BB on HF hospitalization
Five studies reported the outcome of HF 
hospitalization (CIBIS-II, MERIT-HF, SENIORS, 
BEST and AF-CHF), including 2774 patients. The 
pooled analysis showed that BB therapy was not 
associated with a reduction of HF hospitalizations 
(RR 0.94; 95% CI 0.79–1.11, p = 0.46; heterogene-
ity, p = 0.17, I2 = 38% (Fig. 3).
Figure 1. Selection process for articles included in meta-analysis.
680 potentially relevant publications
identied and screened for retrieval
29 full-text articles retrieval 
for detailed review
5 randomized controlled trials and 
3 observational cohort studies included
651 publications excluded 
based on title and abstract
21 studies excluded (no control group, no data
about outcome of all-cause mortality,
follow-up < 6 months, intervention was not
beta-blocker alone, duplicate)
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Sensitivity analysis
Leave-one-out sensitivity analysis on all-cause 
mortality was performed by omitting one study at 
a time, and found that none of the individual stud-
ies significantly influenced the pooled estimate 
of all-cause mortality. Subgroup analyses showed 
that when the pooled analysis of all-cause mortality 
was performed using fixed-effect model, a similar 
result was observed. 
Discussion
Main findings
Meta-analysis of 8 studies involving 34197 
patients revealed that BB were associated with 
a 22% reduction in all-cause mortality. Although 
the finding was limited to observational studies and 
trends favored BB for HF hospitalization did not 
reach statistical significance. Overall, results sup-
ported current evidence-based recommendations 
to pursue BB in all HF patients with or without AF.
Comparison with other studies
The present observed mortality benefit of 
BB in HF and AF diverged from two earlier meta-
analyses [14, 15]. The latest systematic review 
conducted by Kotecha et al. [15] was more recent 
and comprehensive, which was an individual pa-
tient-level meta-analysis. However, in the 2 earlier 
meta-analyses, only RCTs were included and the 
AF group comprised only 17–21% of the whole 
patient cohort. Therefore, the obtained meta-
analyzed results might reflect an under-powered 
analysis. In meta-analysis, the number of patients 
in the included 5 RCTs was 2254 with 407 death-
events, which is still low for survival analysis, and 
the possibility that a lack of power may have played 
a role could not be excluded. Additionally, it is im-
portant to recognize that the included 5 RCTs were 
not specifically designed to assess the effect of BB 
in patients with AF and HF. Above all, the benefits 
of BB for all-cause mortality or HF hospitalizations 
were not observed in the pooled analysis of 5 RCTs, 
consistent with the earlier meta-analyses. 
Our meta-analysis included recently published 
3 observational studies with a low heterogeneity. 
The 3 observational studies from large registries 
included were well designed by using PS analysis 
and multivariable-adjusted Cox regression analysis 
to reduce the effects of confounders (including age, 
sex, underlying disease, medications, and NYHA 
functional class). The mortality benefit associated 
with BB in this analysis was largely driven by the 
results of Danish AF Registry [15]. However, the Ta
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protective effect still remained after removing this 
study using the sensitivity analysis. Furthermore, 
both fixed and random effect models in the pooled 
analysis shows the significantly similar benefit of 
BB treatment. Accordingly, the conclusion that 
the treatment of BB reduces all-cause mortality in 
patients with HF and AF is fairly reliable.
It must be noted the difference between out-
comes in included 5 RCTs and 3 OCSs. The present 
finding that BB therapy decreased mortality in 
patients with HF and AF was limited to the 3 ob-
servational studies. The controversial results may 
be partly explained by differences in methodology, 
patient demographics, HF severity, concomitant 
medication or follow-up duration. First, baseline 
characteristics of patients differed in these stud-
ies. In 5 RCTs, almost all patients included were 
symptomatic HF with NYHA II–IV, while in obser-
vational studies asymptomatic HF with NYHA I 
were also included. It seems that patients included 
in OCSs were at lower risk and had better BB 
tolerance, which all factors associated with lower 
mortality. Second, combined treatment was also an 
important confounder. In 5 RCTs, patients with HF 
and AF were more commonly treated with digoxin 
(88%), while in 3 OCSs, only 40% of patients were 
treated with digoxin. Digoxin had been reported 
to be associated with increased mortality in AF 
patients. The potential synthetic adverse effect of 
digoxin cannot be completely eliminated. Another 
possible reason as mentioned before was that the 
small number of patients in the included 5 RCTs 
was 2254 with 407 death-events which might re-
flect an under-powered analysis. It was admitted 
Figure 3. Effect of beta-blockers on heart failure hospitalization.
Risk ratio 
IV, Random, 95% CI
Risk ratio 
IV, Random, 95% CISElog [risk ratio]Study of subgroup
2.1.1 Five RCTs
2.1.2 Three OCSs
US-Carvedilol
CIBIS-II
MERIT-HF
SENIORS
BEST
Subtotal (95% CI)
–1.0614
0.1493
0.0623
–0.0246
–0.1128
–0.3343
–0.2891
–0.3218
0.0816
0.0272
0.1385
0.687
0.2512
0.2595
0.1694
0.2031
0.35 [0.09, 1.33]
1.16 [0.71, 1.90]
1.06 [0.64, 1.77]
0.98 [0.70, 1.36]
0.89 [0.60, 1.33]
0.97 [0.79, 1.19]
0.72 [0.61, 0.84]
0.75 [0.71, 0.79]
0.72 [0.55, 0.95]
0.74 [0.71, 0.78]
0.5%
3.8%
3.6%
7.7%
5.6%
21.2%
22.3%
45.7%
10.7%
78.8%
Swedish HF cohort
Danish AF cohort
AF-CHF
Subtotal (95% CI)
2 2 2
Heterogeneity Tau  = 0.00; Chi  = 3.06, df = 4 (p = 0.55); I  = 0%
Test for overall effect: Z = 0.27 (p = 0.79)
2 2 2
Heterogeneity Tau  = 0.00; Chi  = 0.32, df = 2 (p = 0.85); I  = 0%
Test for overall effect: Z = 11.61 (p < 0.00001)
2 2 2
Heterogeneity Tau  = 0.00; Chi  = 9.55, df = 7 (p = 0.22); I  = 27%
Test for overall effect: Z = 4.87 (p < 0.00001)
2 2
Test for subgroup differences: Chi  = 6.18 df = 1 (p = 0.01); I  = 83.8%
Weight
0.1
Favours [beta-blocker] Favours [no beta-blocker]
0.01 1 10 100
Total (95% CI) 100.0% 0.78 [0.71, 0.86]
Risk ratio 
M-H, Random, 95% CI
Risk ratio 
M-H, Random, 95% CI
Beta-blocker No beta-blocker
Study of subgroup
AF-CHF
BEST
CIBIS-II
MERIT-HF
SENIORS
Total (95% CI)
229
157
264
282
377
1309
62
104
45
37
58
105
80
36
35
72
328 306
426
146
257
274
361
1464
0.91 [0.70, 1.19]
0.83 [0.69, 1.00]
0.82 [0.55, 1.23]
0.97 [0.63, 1.50]
1.30 [0.95, 1.78]
0.94 [0.79, 1.11]
22.8%
32.8%
13.4%
12.1%
18.9%
100.0%
Total events
2 2 2
Heterogeneity Tau  = 0.01; Chi  = 6.48, df = 4 (p = 0.17); I  = 38%
Test for overall effect: Z = 0.74 (p = 0.46)
WeightTotalTotalEvents Events
0.1
Favours [beta-blocker] Favours [no beta-blocker]
0.01 1 10 100
Figure 2. Effect of beta-blockers on all-cause mortality; CI — confidence interval; OCSs — observational cohort study; 
RCTs — randomized controlled trials.
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that a well-designed randomized trial would be of 
great value according to the highest standards of 
evidence-based medicine. In RCTs the BB were 
well defined, with determined type and dose of 
BB and also heart rate reduction during therapy. 
While observational studies had inherent limita-
tions including nonuniformly defined variables 
across studies. The use of BB differed between 
studies with a different type, dose and course. 
Based on observational studies, whether the doses 
and types of BB affect the effects of BB in patients 
with HF and AF could not be assessed. Until more 
solid evidence is available, it is premature to deny 
patients with AF and HF BB therapy considering 
current evidence.
Possible mechanisms for findings
The optimal heart rate target in AF patients 
is unclear. Moreover, there is limited evidence 
for lenient rate control for AF patients with HF. 
Previous studies have mainly examined sinus 
rhythm, and whether a higher heart rate is associ-
ated with worse outcomes in HF with concomitant 
AF has not been adequately studied. The lack of 
a relationship between heart rate and outcomes 
in patients with HFrEF and concomitant AF has 
previously been described [24–27]. In Rate Con-
trol Efficacy in Permanent Atrial Fibrillation: 
A Comparison between Lenient versus Strict Rate 
Control II (RACE II) trial, lenient rate control 
(< 110 bpm) did not yield worse outcomes than strict 
rate control (< 80 bpm) overall or in the subgroup 
of patients with HF [28, 29]. Potential mortality 
benefit of BB in HF coexisting with AF has been 
observed in the present meta-analysis. However, 
this meta-analysis does not provide the possible 
mechanisms for the survival benefit of BB in those 
patients without specific initial data on heart rate 
and heart rate change during BB treatment. The 
Swedish HF Registry [18] included in the present 
meta-analysis is the only study to assess an as-
sociation of heart rate strata and BB use with 
all-cause mortality in patients with HF in AF. The 
study showed that higher resting heart rate was as-
sociated with increased mortality in AF, which was 
true only if heart rate > 100 bpm. Furthermore, 
BB use was associated with reduced mortality in 
patients with AF, and a lower heart rate was asso-
ciated with reduced mortality in AF only for those 
with heart rate ≤ 100 bpm. In our meta-analysis, 
baseline heart rate of patients were similar among 
included studies, ranging from 79 bpm to 88 bpm 
(< 100 bpm); only 5 RCTs had reported the heart 
rate change for BB treatment at the end of follow-up, 
with a mean heart rate reduction of 10.9 bpm. 
However, in the pooled analysis of 5 RCTs, BB 
use was associated with non-significant reduced 
risk for mortality. Except for small sample size 
of an under-powered analysis, another possible 
explanation is that patients included in the trials 
benefit less from BB use with a baseline heart rate 
< 100 bpm. Patients with a higher heart rate may 
possibly benefit from BB treatment according to 
the results of Swedish HF Registry. 
Implications for clinical practice
Considering the current controversies and 
challenges, more studies on BB in patients with 
HF and AF are still needed. Randomized con-
trolled trials on BB for HF with concomitant AF 
may not be feasible because of ethical reasons. 
Thus, well designed and analyzed cohort studies 
from large registry will be more expected, which 
can give us more information from the real world. 
Future investigation should also help determine 
which patients with AF and HF will derive the 
greatest benefit from BB therapy, including those 
with HFrEF or HFpEF, older or younger, baseline 
heart rate. Additionally, the potential benefit of 
BB and their potential mechanisms beyond HR 
reduction in HF coexisted with AF also require 
further study.
Limitations of the study
The present analysis has several limitations 
that must be taken into consideration when inter-
preting the results. First, observational studies 
were included in the analysis and the mortality 
benefit was largely driven by those OCSs. Be-
cause of the observational nature of the cohort 
study and lack of randomization, the effect of 
unmeasured or residual confounding could not be 
ruled out. Although 3 observational studies from 
large registries were well designed by using PS 
analysis and multivariate regression analysis to 
reduce the effects of confounders, it would be spe-
cially mentioned that not all the studies adjusted 
for all covariates, so combined results should be 
interpreted with caution. Even though a very low 
heterogeneity was showed in the present analysis, 
clinical heterogeneity could not be underestimated. 
Therefore, a random-effect model was used in the 
meta-analysis and sensitivity analysis was also 
used to explore possible study characteristics that 
might have influenced the pooled estimates. Inher-
ent limitations of pooled analysis of studies include 
the limited availability of confounding variables, 
including the type and dose of BB, the course of 
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treatment. Also, in the present analysis, the effects 
of different BB therapies were pooled and thereby 
assumed a class effect. However, specific differ-
ences in pharmacologic profiles may have added 
to the heterogeneity of the cohort and thereby the 
results. Finally, this analysis pooled study group 
estimates and did not assess individual patient 
data, which limits the possibility of adjustment for 
individual patient characteristics.
Conclusions
In summary, the present meta-analysis sug-
gested the potential mortality benefit of BB in 
HF coexisting with AF, and supported current 
evidence-based recommendations to pursue BB for 
those patients. It was concluded that it is prema-
ture to deny patients with AF and HF beta-blocker 
therapy considering current evidence.
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